11.00
price up icon1.85%   0.20
after-market After Hours: 11.05 0.05 +0.45%
loading
Iovance Biotherapeutics Inc stock is traded at $11.00, with a volume of 12.59M. It is up +1.85% in the last 24 hours and up +30.33% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$10.80
Open:
$10.9
24h Volume:
12.59M
Relative Volume:
0.76
Market Cap:
$4.98B
Revenue:
$285.55M
Net Income/Loss:
$-353.86M
P/E Ratio:
-11.58
EPS:
-0.9501
Net Cash Flow:
$-305.02M
1W Performance:
+7.32%
1M Performance:
+30.33%
6M Performance:
+193.33%
1Y Performance:
+444.55%
1-Day Range:
Value
$10.69
$11.13
1-Week Range:
Value
$10.03
$11.13
52-Week Range:
Value
$1.76
$11.13

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Name
Iovance Biotherapeutics Inc
Name
Phone
(650) 260-7120
Name
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Employee
975
Name
Twitter
Name
Next Earnings Date
2026-11-05
Name
Latest SEC Filings
Name
IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
IOVA icon
IOVA
Iovance Biotherapeutics Inc
11.00 4.98B 285.55M -353.86M -305.02M -0.9501
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-25-26 Upgrade Citizens Mkt Perform → Mkt Outperform
Jul-15-25 Downgrade Goldman Neutral → Sell
May-16-25 Downgrade UBS Buy → Neutral
May-12-25 Downgrade Truist Buy → Hold
May-09-25 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Oct-24-24 Initiated UBS Buy
Jul-29-24 Downgrade Piper Sandler Overweight → Neutral
Nov-20-23 Initiated Goldman Buy
Sep-18-23 Reiterated Barclays Overweight
May-30-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-27-23 Upgrade Piper Sandler Neutral → Overweight
Dec-09-22 Downgrade Goldman Buy → Neutral
Oct-31-22 Initiated Guggenheim Neutral
Aug-18-22 Resumed Wells Fargo Equal Weight
Jan-28-22 Upgrade Stifel Hold → Buy
Dec-07-21 Resumed Cowen Outperform
Jun-10-21 Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-20-21 Downgrade Piper Sandler Overweight → Neutral
May-19-21 Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-19-21 Downgrade Stifel Buy → Hold
May-03-21 Initiated Truist Buy
Apr-16-21 Initiated Goldman Buy
Mar-08-21 Upgrade H.C. Wainwright Neutral → Buy
Dec-15-20 Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20 Initiated Mizuho Buy
Mar-04-20 Initiated Barclays Overweight
Feb-26-20 Reiterated H.C. Wainwright Buy
Feb-26-20 Reiterated Oppenheimer Outperform
Dec-18-19 Initiated JMP Securities Mkt Outperform
Oct-01-19 Initiated Stifel Buy
Apr-29-19 Initiated Piper Jaffray Overweight
Feb-28-19 Reiterated Chardan Capital Markets Buy
Feb-07-19 Initiated Robert W. Baird Outperform
Dec-31-18 Resumed B. Riley FBR Buy
Jul-06-18 Reiterated Chardan Capital Markets Buy
Apr-10-18 Upgrade B. Riley FBR, Inc. Neutral → Buy
Mar-13-18 Reiterated B. Riley FBR, Inc. Neutral
Feb-23-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Jan-25-18 Reiterated H.C. Wainwright Buy
Nov-01-17 Reiterated B. Riley FBR, Inc. Buy
View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

pulisher
Sep 25, 2026

Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo! Finance Canada

Sep 25, 2026
pulisher
Sep 25, 2026

IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits

Sep 25, 2026
pulisher
Sep 25, 2026

Iovance Biotherapeutics stock hits 52-week high at 10.98 USD - Investing.com

Sep 25, 2026
pulisher
Sep 25, 2026

Iovance Biotherapeutics Price Target Announced at $15.00/Share by Goldman Sachs - Moomoo

Sep 25, 2026
pulisher
Sep 25, 2026

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits

Sep 25, 2026
pulisher
Sep 24, 2026

Why Iovance Biotherapeutics Stock Was on Fire Today - The Globe and Mail

Sep 24, 2026
pulisher
Sep 24, 2026

IOVA Reinstated by Goldman Sachs -- Buy Rating with Price Target of $15.00 - GuruFocus

Sep 24, 2026
pulisher
Sep 24, 2026

Goldman Sachs Reinstates Buy on Iovance Biotherapeutics (IOVA) w - GuruFocus

Sep 24, 2026
pulisher
Sep 23, 2026

IOVA Stock Quote Price and Forecast - CNN

Sep 23, 2026
pulisher
Sep 22, 2026

Iovance Biotherapeutics, Inc. (IOVA) stock price, news, quote and history - Yahoo Finance UK

Sep 22, 2026
pulisher
Sep 22, 2026

Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 22, 2026
pulisher
Sep 22, 2026

IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits

Sep 22, 2026
pulisher
Sep 22, 2026

Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Sep 22, 2026
pulisher
Sep 21, 2026

Iovance Biotherapeutics stock extends rally after strong earnings and cancer therapy momentum - AD HOC NEWS

Sep 21, 2026
pulisher
Sep 21, 2026

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research

Sep 21, 2026
pulisher
Sep 21, 2026

Iovance Biotherapeutics Stock: 6 Straight Green Days, Up 26% - Trefis

Sep 21, 2026
pulisher
Sep 19, 2026

Why Did Iovance Biotherapeutics (IOVA) Move Today? - finance.yahoo.com

Sep 19, 2026
pulisher
Sep 19, 2026

Iovance Biotherapeutics (IOVA) Is Up 19.2% After Record Q2 Amtagvi Revenue And TIL Pipeline Expansion - finance.yahoo.com

Sep 19, 2026
pulisher
Sep 19, 2026

Iovance Biotherapeutics (IOVA) Stock Fair Value Edges Higher On Amtagvi Margin Progress - Yahoo Finance

Sep 19, 2026
pulisher
Sep 19, 2026

Is Iovance Biotherapeutics (IOVA) Trading At A Premium To Sales? - finance.yahoo.com

Sep 19, 2026
pulisher
Sep 18, 2026

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Moomoo

Sep 18, 2026
pulisher
Sep 18, 2026

Iovance Biotherapeutics (IOVA) Stock Forum and Discussion - Moomoo

Sep 18, 2026
pulisher
Sep 18, 2026

Iovance Biotherapeutics (IOVA) Puts Buyer Nets 64% Gain as Marke - GuruFocus

Sep 18, 2026
pulisher
Sep 18, 2026

Iovance Biotherapeutics (IOVA) Stock Analysis: Unpacking the 65.7% Revenue Growth Potential - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 17, 2026

$Iovance Biotherapeutics (IOVA.US)$ - Moomoo

Sep 17, 2026
pulisher
Sep 17, 2026

$Iovance Biotherapeutics (IOVA.US)$ Talking a profit here and waiting for it to come down closer to 9 ema - Moomoo

Sep 17, 2026
pulisher
Sep 17, 2026

IOVA Maintained by Barclays -- Price Target Raised to $15.00 - GuruFocus

Sep 17, 2026
pulisher
Sep 17, 2026

Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $15 - Moomoo

Sep 17, 2026
pulisher
Sep 17, 2026

IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside PotentialHere’s Why - finance.yahoo.com

Sep 17, 2026
pulisher
Sep 14, 2026

Iovance Biotherapeutics stock hits 52-week high at 9.36 USD By Investing.com - Investing.com Nigeria

Sep 14, 2026
pulisher
Sep 14, 2026

Iovance Biotherapeutics stock hits 52-week high at 9.36 USD - Investing.com

Sep 14, 2026
pulisher
Sep 12, 2026

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - Stocktwits

Sep 12, 2026
pulisher
Sep 10, 2026

Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits

Sep 10, 2026
pulisher
Sep 10, 2026

Iovance Biotherapeutics' Chief Regulatory Officer Reports RSU Vesting and Tax Withholding Transactions - Kalkine Media

Sep 10, 2026
pulisher
Sep 10, 2026

Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com Australia

Sep 10, 2026
pulisher
Sep 09, 2026

Iovance Biotherapeutics (IOVA) Slips 3.10% to $8.43 as Support at $8.01 Comes Into FocusAlgorithmic Stock Picks - careplusvn.com

Sep 09, 2026
pulisher
Sep 08, 2026

Iovance Biotherapeutics stock trends on sector momentum, Q2 beat - scanx.trade

Sep 08, 2026
pulisher
Sep 08, 2026

Why Is IOVA Stock Falling Today? - Stocktwits

Sep 08, 2026
pulisher
Sep 08, 2026

NFLX: Netflix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 08, 2026
pulisher
Sep 06, 2026

How Iovance Biotherapeutics Inc. (IOVA) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 06, 2026
pulisher
Sep 05, 2026

Iovance Biotherapeutics Stock Price Forecast. Should You Buy IOVA? - StockInvest.us

Sep 05, 2026
pulisher
Sep 04, 2026

Iovance Biotherapeutics, Inc. (IOVA) Latest Press Releases & Corporate News - Yahoo Finance

Sep 04, 2026
pulisher
Sep 04, 2026

Iovance Biotherapeutics, Inc. (IOVA) Latest Stock News & Headlines - Yahoo Finance

Sep 04, 2026
pulisher
Sep 04, 2026

Iovance Biotherapeutics to Present at Upcoming Conferences - The Manila Times

Sep 04, 2026
pulisher
Sep 01, 2026

Iovance Biotherapeutics (IOVA) Stands Out with Strong Quant Rati - GuruFocus

Sep 01, 2026
pulisher
Aug 29, 2026

Iovance Biotherapeutics (IOVA) Wins FDA Trial Clearance, Is The Stock Still 54% Undervalued? - sahmcapital.com

Aug 29, 2026
pulisher
Aug 27, 2026

Iovance Biotherapeutics Inc. (IOVA) Peer Comparison – Compare with Others - Value Research

Aug 27, 2026
pulisher
Aug 27, 2026

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Eastern Progress

Aug 27, 2026
pulisher
Aug 22, 2026

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates - Eastern Progress

Aug 22, 2026
pulisher
Aug 21, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Aug 21, 2026

Iovance Biotherapeutics Inc Stock (IOVA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
Cap:     |  Volume (24h):